[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Huang SD, Yuan Y, Liu XH, Gong DJ, Bai CG, Wang F, Luo JH, Xu ZY: Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas. BMC Cancer; 2009;9:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Self-renewal and chemotherapy resistance of p75NTR positive cells in esophageal squamous cell carcinomas.
  • BACKGROUND: p75NTR has been used to isolate esophageal and corneal epithelial stem cells.
  • In the present study, we investigated the expression of p75NTR in esophageal squamous cell carcinoma (ESCC) and explored the biological properties of p75NTR+ cells.
  • METHODS: p75NTR expression in ESCC was assessed by immunohistochemistry. p75NTR+ and p75NTR- cells of 4 ESCC cell lines were separated by fluorescence-activated cell sorting.
  • Differentially expressed genes between p75NTR+ and p75NTR- cells were determined by real-time quantitative reverse transcription-PCR.
  • Sphere formation assay, DDP sensitivity assay, 64copper accumulation assay and tumorigenicity analysis were performed to determine the capacity of self-renewal, chemotherapy resistance and tumorigenicity of p75NTR+ cells.
  • The percentage of p75NTR+ cells was 1.6%-3.7% in Eca109 and 3 newly established ESCC cell lines.
  • CONCLUSION: Our results demonstrated that p75NTR+ cells possess some characteristics of CSCs, namely, self-renewal and chemotherapy resistance.
  • Chemotherapy resistance of p75NTR+ cells may probably be attributable to decreased expression of CTR1.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Drug Resistance, Neoplasm. Esophageal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Neoplastic Stem Cells / metabolism. Nerve Tissue Proteins / metabolism. Receptors, Nerve Growth Factor / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Growth Processes. Cell Line, Tumor. Cell Proliferation. Cisplatin / pharmacology. Copper Radioisotopes / metabolism. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Nuclear Proteins / metabolism. Polycomb Repressive Complex 1. Proto-Oncogene Proteins / metabolism. Random Allocation. Repressor Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Spheroids, Cellular / drug effects. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jun;57(6):781-8 [16170571.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5096-103 [16951226.001]
  • [Cites] Mol Pharmacol. 2006 Oct;70(4):1390-4 [16847145.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1797-803 [17234707.001]
  • [Cites] Nat Chem Biol. 2007 May;3(5):268-73 [17417631.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1750-62 [17456779.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1635-44 [17395774.001]
  • [Cites] J Dermatol Sci. 2007 Oct;48(1):43-52 [17644316.001]
  • [Cites] Cancer Genomics Proteomics. 2007 May-Jun;4(3):165-74 [17878520.001]
  • [Cites] Exp Eye Res. 2008 Jan;86(1):34-40 [17980361.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1109-23 [18083101.001]
  • [Cites] Mol Cancer. 2007;6:75 [18034892.001]
  • [Cites] Biol Reprod. 2001 Feb;64(2):464-72 [11159348.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6559-65 [12438251.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):225-39 [12787561.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4017-26 [12821936.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Mar;53(3):239-46 [14648017.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4578-88 [15240550.001]
  • [Cites] Science. 1993 Jul 16;261(5119):345-8 [8332899.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1217-24 [8055441.001]
  • [Cites] EMBO J. 1997 Aug 15;16(16):4999-5005 [9305641.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • (PMID = 19134212.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BMI1 protein, human; 0 / Copper Radioisotopes; 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Nerve Growth Factor; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2637890
  •  go-up   go-down


2. Lyall DA, Srinivasan S, Roberts F: Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report.
  • A 67-year-old man with a history of multiple myeloma (treated with chemotherapy) was referred with a left hyperaemic conjunctival lesion covering almost 360° of the limbus and extending onto the corneal surface.
  • Initial treatment consisted of topical and intralesional injections of interferon α-2b.
  • The patient subsequently developed limbal stem cell deficiency resulting in a persistent non-healing corneal epithelial defect.
  • This was successfully managed with total excisional biopsy of the lesion, combined with limbal stem cell autograft (from the fellow eye) and amniotic membrane transplantation.
  • Histopathology revealed a conjunctival squamous cell carcinoma.
  • The corneal epithelium completely healed postoperatively and there is no evidence of tumour recurrence at 1 year follow-up.
  • This case highlights a rare case of advanced ocular surface neoplasia causing secondary limbal stem cell deficiency.
  • Medical and surgical management of ocular surface neoplasia with limbal stem cell transplantation is effective in treating such cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22121391.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027379
  •  go-up   go-down


3. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M: 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol; 2010;4:801-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.
  • OBJECTIVE: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).
  • PARTICIPANTS: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.
  • Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication.
  • The number of initial treatment was six cycles.
  • Additional chemotherapy was given after the initial treatment cycles, only for one case.
  • CONCLUSIONS: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy.
  • It is well-tolerated and an effective method of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2009 Aug;28(7):821-4 [19574900.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Am J Ophthalmol. 1984 May;97(5):547-59 [6720832.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1600-1 [9400803.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Ophthalmologica. 1979;178(4):198-203 [481865.001]
  • [Cites] Am J Ophthalmol. 1976 Feb;81(2):198-206 [766640.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 20689797.001).
  • [ISSN] 1177-5483
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2915867
  • [Keywords] NOTNLM ; chemotherapy / fluorouracil / neoplasia / treatment cycles
  •  go-up   go-down


Advertisement
4. McKelvie PA, Daniell M: Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia. Br J Ophthalmol; 2001 Sep;85(9):1115-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia.
  • BACKGROUND/AIMS: Topical mitomycin C (MMC) therapy has been used for treatment of ocular surface squamous neoplasia (OSSN) since 1994.
  • METHODS: Impression cytology was studied in four patients with ocular surface squamous neoplasia, either primary or recurrence after previous excisional biopsy.
  • These changes mimicked those seen following radiation therapy in uterine cervix.
  • Changes of increased nuclear and cell size with increased N/C ratio were seen in some dysplastic cells.
  • The predominant form of cell death was apoptosis with fewer cells showing necrosis.
  • CONCLUSIONS: MMC appears to produce cell death in OSSN by apoptosis and necrosis.
  • MMC related changes may persist in ocular surface epithelium for at least 8 months following MMC therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Carcinoma, Squamous Cell / drug therapy. Eye / drug effects. Eye Neoplasms / drug therapy. Mitomycin / pharmacology
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / pathology. Corneal Diseases / drug therapy. Corneal Diseases / pathology. Female. Humans. Male. Nucleic Acid Synthesis Inhibitors / pharmacology. Nucleic Acid Synthesis Inhibitors / therapeutic use. Prospective Studies. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Eye Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1645-6 [1454337.001]
  • [Cites] Diagn Cytopathol. 1994;11(3):246-9 [7867466.001]
  • [Cites] J Clin Pathol. 1995 Apr;48(4):314-7 [7615848.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Aust N Z J Ophthalmol. 1997 Nov;25(4):269-76 [9395829.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Br J Ophthalmol. 1997 Nov;81(11):984-8 [9505824.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1756-60; discussion 1761 [10485547.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Oct;21(5):387-96 [10560521.001]
  • [Cites] BJU Int. 2000 May;85(7):911-7 [10792176.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Pathology. 2000 Aug;32(3):186-90 [10968392.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):777-83 [11048728.001]
  • [Cites] Br J Cancer. 1972 Aug;26(4):239-57 [4561027.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):117-21 [2776594.001]
  • [Cites] Cell. 1994 Aug 26;78(4):539-42 [8069905.001]
  • (PMID = 11520767.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Nucleic Acid Synthesis Inhibitors; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1724127
  •  go-up   go-down


5. Uchimiya H, Furukawa T, Okamoto M, Nakajima Y, Matsushita S, Ikeda R, Gotanda T, Haraguchi M, Sumizawa T, Ono M, Kuwano M, Kanzaki T, Akiyama S: Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res; 2002 May 15;62(10):2834-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymidine phosphorylase (TP), an enzyme involved in the reversible conversion of thymidine to thymine, is identical to an angiogenic factor, platelet-derived endothelial cell growth factor (PD-ECGF).
  • Both TP and one of the TP-degradation products of thymidine 2-deoxy-D-ribose (dRib) display endothelial cell chemotactic activity in vitro and angiogenic activity in vivo.
  • Therefore, we investigated the ability of lRib to inhibit the range of biological activities of TP and dRib. lRib suppressed both dRib-induced endothelial cell migration in a chemotaxis assay and endothelial tube formation induced by dRib in a collagen gel. lRib could also suppress the biological effects of TP in vivo assays of angiogenesis and tumor growth.
  • Thus, in a corneal assay of angiogenesis, lRib inhibited angiogenesis induced by the implantation of recombinant TP.
  • In a tumor growth assay, lRib treatment considerably decreased the growth rate of KB/TP cells xenografted into nude mice and also resulted in an increase in the proportion of apoptotic cells in KB/TP tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Deoxyribose / pharmacology. Enzyme Inhibitors / pharmacology. Neovascularization, Pathologic / drug therapy. Thymidine Phosphorylase / antagonists & inhibitors
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Division / physiology. Chemotaxis / drug effects. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Physiologic / drug effects. Rats. Rats, Sprague-Dawley. Stereoisomerism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12019161.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 533-67-5 / Deoxyribose; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


6. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


7. Tunc M, Erbilen E: Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma. Am J Ophthalmol; 2006 Oct;142(4):673-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
  • PURPOSE: To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC).
  • METHODS: Two patients who had positive margins following surgical excision of CCSC were treated by topical CSA (0.05%) four times a day for 12 weeks, and topical MMC (0.01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment.
  • CONCLUSIONS: As an adjunctive treatment, topical CSA (0.05%) combined with MMC (0.01%), may prevent tumor recurrence and provide excellent ocular surface healing in diffuse CCSC.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Cyclosporine / therapeutic use. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Antibiotics, Antineoplastic / therapeutic use. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011863.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


8. Shields CL, Naseripour M, Shields JA: Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol; 2002 May;133(5):601-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin C for extensive recurrent conjunctival and corneal squamous cell carcinoma (SCC).
  • Ten patients (ten eyes) with extensive recurrent conjunctival and corneal SCC were studied.
  • The patients received topical mitomycin C 0.04% one drop four times daily in the eye with SCC.
  • Treatment cycles were defined as 1 week using medication followed by 1 week without medication.
  • Such treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • The main outcome measures were tumor response and medication-related complications.
  • Before referral, the patients had undergone a median of two previous conjunctival tumor resections revealing the diagnosis of in situ SCC in three cases and locally invasive SCC in six cases.
  • At presentation, the tumor involved the limbus and cornea in all ten eyes, forniceal conjunctiva in three eyes, and tarsal conjunctiva in one eye.
  • The extensive tumor affected a median of 10 clock hours of limbal conjunctiva and 10 clock hours of cornea, with corneal epithelial invasion for a median of 50% (range 20%-100%) of its surface.
  • Mitomycin C 0.04% four times daily was applied for a median of three cycles (range 1-4 cycles).
  • CONCLUSIONS: Based on this small series, topical mitomycin C 0.04% appears to be a safe and effective therapy for conjunctival or corneal SCC, even when there is extensive recurrent tumor.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Drug Evaluation. Female. Humans. Male. Middle Aged. Prospective Studies. Safety. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Ophthalmol. 2003 Jan;135(1):122-3; author reply 123-4 [12504721.001]
  • (PMID = 11992855.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


9. Karasawa K, Matsuda H, Tanaka A: Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog. J Small Anim Pract; 2008 Apr;49(4):208-10
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial keratectomy and topical mitomycin C as therapy for a corneal squamous cell carcinoma in a dog.
  • A 10-year-old female West Highland white terrier was presented with refractory hyperplastic keratitis of the left cornea of one month's duration.
  • At this time, a vascularised and rough lesion 5 mm in diameter was observed on the left cornea.
  • The corneal neoplasm was surgically removed and histologically diagnosed as a squamous cell carcinoma.
  • For two months after the surgery, 0.04 percent mitomycin C (MMC) eye drops were applied as adjuvant chemotherapy.
  • Primary corneal squamous cell carcinoma with no history of keratoconjunctivitis sicca is rare in dogs.
  • In the present report, surgical removal of the neoplasm was combined with the topical administration of the anticancer drug mitomycin C and a good prognosis was obtained.
  • The result indicates that the combination treatment used in this case may be an appropriate therapeutic choice for corneal squamous cell carcinoma in dogs.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Corneal Diseases / veterinary. Dog Diseases / drug therapy. Dog Diseases / surgery. Eye Neoplasms / veterinary
  • [MeSH-minor] Administration, Topical. Animals. Combined Modality Therapy. Corneal Surgery, Laser / methods. Corneal Surgery, Laser / veterinary. Dogs. Female. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725585.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin
  •  go-up   go-down


10. Panda A, Bajaj MS, Balasubramanya R, Prakash G: Topical mitomycin C for conjunctival-corneal squamous cell carcinoma. Am J Ophthalmol; 2003 Jan;135(1):122-3; author reply 123-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C for conjunctival-corneal squamous cell carcinoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • (PMID = 12504721.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


11. Russell HC, Chadha V, Lockington D, Kemp EG: Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol; 2010 Oct;94(10):1316-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
  • The aim of this study is to determine outcomes and complications following such treatment.
  • METHODS: This study is a retrospective review of patients treated with topical MMC for ocular surface neoplasia, including primary acquired melanosis (PAM), melanoma, corneal-conjunctival intraepithelial neoplasia (CCIN), squamous cell carcinoma (SCC) and sebaceous gland carcinoma (SGC).
  • Data regarding diagnosis, short- and long-term outcomes, and short- and long-term complications, were recorded.
  • 21 received MMC as primary therapy and 37 as surgical adjuvant.
  • The regimen was 0.04% MMC four times a day for 3 weeks on, 3 weeks off, 3 weeks on, with topical steroid and lubricants throughout.
  • Overall, 26% developed recurrent disease at a mean of 13 months post treatment.
  • Short-term complications occurred in 52%, but only 7% required treatment cessation.
  • Long-term complications such as persisting keratoconjunctivitis, epiphora and corneal problems, occurred in 31%.
  • CONCLUSION: The results confirm the effectiveness of topical MMC chemotherapy in the management of ocular surface neoplasia.
  • Self-limiting short-term complications were common; however, limbal stem cell deficiency appears to be a significant long-term complication of treatment, occurring in 12%.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


12. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, Srivannaboon S: Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea; 2005 May;24(4):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
  • PURPOSE: To demonstrate the efficacy of topical 0.002% mitomycin C (MMC) as an adjunctive and alternative treatment in primary and recurrent conjunctival-corneal intraepithelial neoplasia (CCIN) and squamous cell carcinoma (SCC).
  • All cases were treated with topical 0.002% MMC 4 times daily.
  • The tumor size pre- and post-treatment, clinical response, and ocular complications were evaluated.
  • Before MMC treatment, 6 eyes (85.7%) had recurrences after surgical excision.
  • MMC 0.002% 4 times daily was applied for a period of 5.4 +/- 4.4 weeks (range, 2-14).
  • Side effects of MMC therapy included ocular irritation, mild conjunctival hyperemia, and punctate keratopathy.
  • The mean follow-up time was 30.7 +/- 15 months (range, 2-52) with no evidence of clinical recurrence in any case.
  • CONCLUSIONS: Topical 0.002% MMC showed a favorable outcome as an adjunctive and alternative treatment of CCIN and SCC with regression of primary and recurrent tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829803.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


13. Khokhar S, Soni A, SinghSethi H, Sudan R, Sony P, Pangtey MS: Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea; 2002 Mar;21(2):189-91
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia.
  • PURPOSE: To report the outcome of combined excision, cryotherapy, and antimetabolite treatment of recurrent ocular surface squamous neoplasia.
  • METHODS: The patients with recurrent ocular surface squamous neoplasia were treated by excision of lesion, cryotherapy of limbus, and conjunctival margin followed by 0.02% Mitomycin C application at the time of surgery.
  • RESULTS: A total of five eyes of five patients with recurrent ocular surface squamous neoplasia were treated by combined excision, cryotherapy, and Mitomycin C.
  • Histopathologic diagnosis included invasive squamous cell carcinoma in four cases and squamous dysplasia in one case.
  • CONCLUSION: Combining excision with cryotherapy and Mitomycin C application at the time of surgery is a very effective therapy for recurrent ocular surface squamous neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / therapy. Cryosurgery. Eye Neoplasms / therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11862092.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Semenova EA, Milman T, Finger PT, Natesh S, Kurli M, Schneider S, Iacob CE, McCormick SA: The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia. Am J Ophthalmol; 2009 Nov;148(5):772-778.e1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia.
  • PURPOSE: To determine the reliability and role of conjunctival exfoliative cytologic and histopathologic diagnosis of biopsied tissue in ocular surface squamous neoplasia.
  • DESIGN: Retrospective review of an interventional case series of patients biopsied and treated for squamous conjunctival and corneal neoplasia.
  • For the purposes of this study, three ocular pathologists reviewed the results of cytologic and biopsied tissue in a masked fashion.
  • Evaluation of subsequent biopsy revealed a 98% concordance between the pathologists in interpretation of biopsied tissue as no dysplasia vs any degree of dysplasia.
  • Cytologic evaluation was capable of distinguishing a neoplastic from nonneoplastic process before tissue biopsy in 80% of cases.
  • It was used in the settings of recurrent tumor and for follow-up care of patients treated with topical chemotherapy.
  • Although cytologic smears cannot replace incisional or excisional biopsy for definitive diagnosis, exfoliative cytologic analysis can play an important role in the diagnosis and management of patients with ocular surface squamous neoplasia.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Conjunctiva / pathology. Conjunctival Neoplasms / diagnosis. Corneal Diseases / diagnosis. Eye Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Cytological Techniques. Female. Humans. Male. Neoplasm Staging. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660734.001).
  • [ISSN] 1879-1891
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Umebayashi Y, Enomoto H, Ogasawara M: Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules. J Dermatol; 2004 Oct;31(10):802-5
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug eruption due to peplomycin: an unusual form of Stevens-Johnson syndrome with pustules.
  • The patient had squamous cell carcinoma on the scalp and underwent preoperative neoadjuvant chemotherapy with peplomycin.
  • On the fifth day of the chemotherapy, he developed a fever and multiple dusky violaceous erythematous areas and pustules on his trunk, thighs, and palms.
  • Erosive erythema and erosions also developed on his soles, scrotum, and oral mucosa.
  • Additionally, the patient developed conjunctivitis and corneal erosions.
  • After administration of the regular daily dose, the patient had a relapse of fever, eruptions, stomatitis, corneal erosions, and liver dysfunction.
  • Therefore, a definite diagnosis of drug eruption due to peplomycin was made.
  • [MeSH-major] Drug Eruptions / pathology. Peplomycin / adverse effects. Skin Diseases, Vesiculobullous / chemically induced. Stevens-Johnson Syndrome / chemically induced
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Follow-Up Studies. Hand Dermatoses / chemically induced. Hand Dermatoses / drug therapy. Hand Dermatoses / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Mouth Mucosa / pathology. Prednisolone / therapeutic use. Risk Assessment. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Stevens-Johnson syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15672707.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


16. Holcombe DJ, Lee GA: Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia. Am J Ophthalmol; 2006 Oct;142(4):568-71
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical interferon alfa-2b for the treatment of recalcitrant ocular surface squamous neoplasia.
  • PURPOSE: To evaluate topical interferon alfa-2b (IFN-alpha2b) for the treatment of recalcitrant ocular surface squamous neoplasia (OSSN).
  • METHODS: Ten patients with recalcitrant OSSN were treated with topical IFN-alpha2b (1 million IU/ml) four times a day until clinical resolution of the lesion or until the lesion appeared nonresponsive-that is, treatment failure.
  • RESULTS: Eight of 10 patients achieved clinical resolution from topical IFN-alpha2b treatment.
  • One patient developed invasive squamous cell carcinoma and underwent exenteration.
  • The other patient required further mitomycin C therapy to achieve clinical resolution.
  • CONCLUSIONS: Topical IFN-alpha2b is an important treatment modality for recalcitrant OSSN; it avoids the risks of further limbal stem cell destruction from other agents and surgical excision.
  • If invasive disease is diagnosed at any stage, topical therapy is contraindicated, necessitating surgical excision.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Recombinant Proteins. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011846.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


17. Karp CL, Galor A, Lee Y, Yoo SH: Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pilot study. Ocul Immunol Inflamm; 2010 Aug;18(4):254-60
Hazardous Substances Data Bank. ACETAMINOPHEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pilot study.
  • PURPOSE: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNalpha2b) for treatment of ocular surface squamous neoplasia (OSSN).
  • The mean time to resolution was 47 days.
  • During the follow-up time after resolution of the lesion (mean 41 months), one patient had disease recurrence 7 months after clinical resolution.
  • CONCLUSION: PEGIFNalpha2b may be a viable medical alternative for the treatment of OSSN.
  • [MeSH-major] Antiviral Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Polyethylene Glycols / therapeutic use
  • [MeSH-minor] Acetaminophen / therapeutic use. Aged. Corneal Diseases / drug therapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Ophthalmic Solutions / therapeutic use. Pilot Projects. Prospective Studies. Recombinant Proteins. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662655.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 362O9ITL9D / Acetaminophen; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


18. Fujita K, Miyamoto T, Okada Y, Ishikawa N, Saika S: Expression pattern of sonic hedgehog and effect of topical mitomycin C on its expression in human ocular surface neoplasms. Jpn J Ophthalmol; 2008 May-Jun;52(3):190-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Conjunctival tissues obtained from two normal subjects, two patients with squamous cell carcinoma of the ocular surface (conjunctiva), and one patient with ocular epithelial dysplasia were used in this study.
  • On the other hand, squamous cell carcinoma cells markedly expressed Shh with positive staining for Patched 1(Ptc), the cell surface receptor of Shh.
  • Similar marked expression of Shh was detected in the patient with ocular epithelial dysplasia, and this Shh expression was almost eliminated following topical mitomycin C treatment.
  • A cell culture experiment was conducted to examine the effect of mitomycin C on Shh expression in a cultured squamous cell carcinoma cell line.
  • Reduction of Shh expression might be involved in the therapeutic efficacy of topical mitomycin C for ocular surface epithelial neoplasms.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Hedgehog Proteins / metabolism. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Epithelium, Corneal / drug effects. Epithelium, Corneal / metabolism. Epithelium, Corneal / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Male. Middle Aged. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):34-42 [12573433.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):361-72 [12044012.001]
  • [Cites] Int J Cancer. 1989 Jan 15;43(1):152-7 [2783415.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Development. 2004 Mar;131(6):1289-98 [14960493.001]
  • [Cites] Curr Opin Neurobiol. 2002 Feb;12(1):57-63 [11861165.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):548-52 [11874760.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Cell Signal. 2003 Feb;15(2):141-9 [12464385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3438-43 [10725363.001]
  • [Cites] Am J Ophthalmol. 2006 Oct;142(4):568-71 [17011846.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Cornea. 1999 May;18(3):343-52 [10336039.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(11):1855-61 [16750652.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] Curr Eye Res. 1999 Jun;18(6):477-89 [10435835.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):216-7 [10700170.001]
  • [Cites] Jpn J Ophthalmol. 2000 Nov-Dec;44(6):639-42 [11094180.001]
  • [Cites] Ocul Surf. 2003 Apr;1(2):66-73 [17075634.001]
  • (PMID = 18661269.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hedgehog Proteins; 0 / SHH protein, human; 50SG953SK6 / Mitomycin
  •  go-up   go-down


19. Siganos CS, Kozobolis VP, Christodoulakis EV: The intraoperative use of mitomycin-C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea; 2002 Jan;21(1):12-6
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seven patients (eight eyes), three men and four women, aged 56 to 87 years (mean, 73.8 years), with lesions suspicious for corneal or conjunctival neoplasia, were operated on between October 1998 and March 2000.
  • Histopathologic study showed four cases of squamous cell carcinoma, one case of carcinoma in situ, two cases of dysplasia, and one case of actinic keratosis.
  • Of the eight eyes, no clinical recurrence of the lesion occurred in seven eyes, whereas one eye with squamous cell carcinoma showed mild recurrence 5 months after surgery and was successfully treated with topical mitomycin-C.
  • CONCLUSION: The excision of conjunctival and corneal epithelial neoplasia combined with the intraoperative use of mitomycin-C seems to reduce the recurrence rate.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / surgery. Corneal Diseases / surgery. Epithelial Cells / transplantation. Eye Neoplasms / surgery. Limbus Corneae / cytology. Mitomycin / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma in Situ / drug therapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Cell Transplantation. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2002 Nov;21(8):840-1; author reply 841-2 [12410051.001]
  • [ErratumIn] Cornea. 2003 Mar;22(2):189.
  • (PMID = 11805500.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


20. Zaki AA, Farid SF: Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea; 2009 Oct;28(9):986-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
  • PURPOSE: The aim of this work is to report the long-term results of using immunotherapy for the management of cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma after surgical excision of the neoplasm.
  • METHODS: Ten eyes of 10 patients with cornea and conjunctiva intraepithelial neoplasia or squamous cell carcinoma had wide surgical excisions of the neoplasm after evaluation of the level of corneal involvement using ultrasound biomicroscopy.
  • All eyes received topical cyclosporine A (0.05%) and topical mitomycin C (0.01%) 4 times daily for 12 weeks after surgery.
  • Epithelial toxicity (punctate keratopathy) occurred in 3 eyes, ocular irritation and mild conjunctival hyperemia in 5 eyes, and lid toxicity in 2 cases during the treatment with mitomycin C.
  • There were no serious complications that necessitated stopping the treatment.
  • CONCLUSION: During a 2-year follow-up period, the use of topical cyclosporine A (0.05%) combined with mitomycin C (0.01%) as an adjunctive treatment after surgical excision in cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma was found to prevent tumor recurrence, especially in extensive lesions, when surgical excision cannot ensure a tumor-free margin.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Eye Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclosporine / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Mitomycin / administration & dosage. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2012 Apr;31(4):465 [22314824.001]
  • [CommentIn] Cornea. 2011 Apr;30(4):486; author reply 486-7 [21107255.001]
  • (PMID = 19724215.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


21. Bhutto AM, Shaikh A, Nonaka S: Incidence of xeroderma pigmentosum in Larkana, Pakistan: a 7-year study. Br J Dermatol; 2005 Mar;152(3):545-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is a rare autosomal recessive inherited disorder caused by a defect in the normal repair of DNA of various cutaneous cell types damaged by exposure to ultraviolet radiation.
  • Twenty-nine patients developed ocular symptoms: photophobia, conjunctivitis, corneal keratitis and lid ulcer.
  • Histopathological findings revealed that six patients had squamous cell carcinoma (SCC) on the face, head, ear or lip.
  • The majority of cases (20/36, 55.6%) were from the Brohi tribe (skin type III), while the remaining cases (16/36, 44.4%) were from the Sindhi population (skin type IV).
  • The large number of XP patients seen in those with skin type III (Brohi tribe) compared with skin type IV (Sindhi population) indicates that the skin type and the race has a considerable value in the pathogenesis of XP.
  • All patients were treated according to disease severity by prescribing oral antibiotics, local steroids, sunscreens and/or chemotherapy followed by irradiation in malignant cases.

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787826.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. Poothullil AM, Colby KA: Topical medical therapies for ocular surface tumors. Semin Ophthalmol; 2006 Jul-Sep;21(3):161-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical medical therapies for ocular surface tumors.
  • We review the use of three topical medications for the therapy of ocular surface tumors: mitomycin C, 5-fluorouracil, and interferon alpha-2B.
  • Topical agents were used as both primary and adjuvant therapy.
  • Rates of tumor regression for CIN and squamous cell carcinoma ranged from 80 to 96%, and 70% of pigmented tumors regressed after an average follow-up of 27 months.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymphoma / drug therapy. Lymphoma / pathology. Mitomycin / administration & dosage. Mitomycin / adverse effects. Recombinant Proteins. Sebaceous Gland Neoplasms / drug therapy. Sebaceous Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912014.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b; U3P01618RT / Fluorouracil
  • [Number-of-references] 52
  •  go-up   go-down


23. Saika S, Miyamoto T, Kawashima Y, Jinza K, Okada Y, Yamanaka O, Ohnishi Y, Ooshima A: Alterations in ultrastructure and c-met expression in a case of ocular epithelial dysplasia following topical mitomycin C treatment. Jpn J Ophthalmol; 2000 Nov-Dec;44(6):639-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations in ultrastructure and c-met expression in a case of ocular epithelial dysplasia following topical mitomycin C treatment.
  • PURPOSE: Topical mitomycin C (MMC) administration is reportedly effective in treating ocular surface neoplasms such as squamous cell carcinoma.
  • We examined the ultrastructure of and c-met (hepatocyte growth factor receptor) expression in dysplastic epithelial cells from this case to evaluate the efficacy of MMC treatment.
  • METHODS: Specimens of dysplastic epithelial tissue from the corneo-limbal region of a 62-year-old man were obtained before and after topical application of MMC.
  • RESULTS: Following topical application of MMC, the dysplastic epithelium exhibited multilayered epithelial cells similar to those seen before treatment.
  • Also, the marked immunoreactivity to c-met in the dysplastic epithelial cells before MMC treatment was decreased after treatment.
  • The expression of c-met protein was also reduced.
  • Thus, topical MMC was effective in treating epithelial dysplasia of the ocular surface, with no recurrence 15 months post-therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Corneal Diseases / drug therapy. Epithelium, Corneal / ultrastructure. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use. Proto-Oncogene Proteins c-met / metabolism

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094180.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


24. Scheinfeld N: A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. J Drugs Dermatol; 2007 Mar;6(3):352-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a number of medications approved for nondermatologic use have proved useful against dermatologic diseases.
  • Deferasirox--an oral iron chelator--could be an effective treatment against porphyria cutanea tarda, hemochromatosis, and pathogens such as mucor that thrive in iron rich environments.
  • Bortezomib, a proteasome inhibitor and multiple myeloma treatment, may be effective against nodular amyloid and has been effectively used against squamous cell carcinoma; although trials demonstrate it is ineffective against metastatic melanoma.
  • Dasatinib is a multi-targeted tyrosine kinase inhibitor active in vitro against most cell lines containing BCR-ABL mutations that confer resistance to imatinib.
  • This article speculates that cyclosporine eye drops would also be useful for any disease causing ectropion or eclabion of the eye as well as toxic epidermal necrolysis-related eye pathology (in particular corneal scarring).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzoates / therapeutic use. Boronic Acids / therapeutic use. Cyclosporine / therapeutic use. Iron Chelating Agents / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrazines / therapeutic use. Pyrimidines / therapeutic use. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy. Thiazoles / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373201.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Boronic Acids; 0 / Iron Chelating Agents; 0 / Ophthalmic Solutions; 0 / Protein Kinase Inhibitors; 0 / Pyrazines; 0 / Pyrimidines; 0 / Thiazoles; 0 / Triazoles; 69G8BD63PP / Bortezomib; 83HN0GTJ6D / Cyclosporine; RBZ1571X5H / Dasatinib; V8G4MOF2V9 / deferasirox
  • [Number-of-references] 36
  •  go-up   go-down


25. Aoki S, Cho SH, Ono M, Kuwano T, Nakao S, Kuwano M, Nakagawa S, Gao JQ, Mayumi T, Shibuya M, Kobayashi M: Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs; 2006 Mar;17(3):269-78
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bastadin 6 also inhibited VEGF- or bFGF-induced tubular formation (0.1 micromol/l, 6 h treatment) and VEGF-induced migration (1 micromol/l, 4 h treatment) of HUVECs.
  • Moreover, bastadin 6 almost completely blocked VEGF- or bFGF-induced in vivo neovascularization in the mice corneal assay and suppressed growth of s.c. inoculated A431 solid tumor in nude mice (100 mg/kg, i.p.).
  • Bastadin 6 induced cell death of HUVECs with an apoptotic phenotype, whereas it showed no effect on the VEGF-induced auto-phosphorylation of VEGF receptors Flt-1 and KDR/Flk-1.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Apoptosis / drug effects. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Endothelial Cells / drug effects. Tyrosine / analogs & derivatives
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cornea / blood supply. Fibroblast Growth Factor 2 / antagonists & inhibitors. Fibroblast Growth Factor 2 / pharmacology. Halogenated Diphenyl Ethers. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. NIH 3T3 Cells. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Neovascularization, Physiologic / drug effects. Porifera / chemistry. Rats. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor A / pharmacology. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520655.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Halogenated Diphenyl Ethers; 0 / Vascular Endothelial Growth Factor A; 0 / bastadin 6; 103107-01-3 / Fibroblast Growth Factor 2; 42HK56048U / Tyrosine; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


26. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res; 2006 Sep 1;66(17):8715-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The growth of solid tumors is dependent on the continued stimulation of endothelial cell proliferation and migration resulting in angiogenesis.
  • AMG 706 inhibited human endothelial cell proliferation induced by VEGF, but not by basic fibroblast growth factor in vitro, as well as vascular permeability induced by VEGF in mice.
  • Oral administration of AMG 706 potently inhibited VEGF-induced angiogenesis in the rat corneal model and induced regression of established A431 xenografts.
  • Histologic analysis of tumor xenografts from AMG 706-treated animals revealed an increase in endothelial apoptosis and a reduction in blood vessel area that preceded an increase in tumor cell apoptosis.
  • In summary, AMG 706 is an orally bioavailable, well-tolerated multikinase inhibitor that is presently under clinical investigation for the treatment of human malignancies.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Indoles / therapeutic use. Niacinamide / analogs & derivatives. Proto-Oncogene Proteins c-kit / drug effects
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Cell Line. Cell Line, Tumor. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiology. Female. Fibroblasts / drug effects. Humans. Leukemia, Megakaryoblastic, Acute / drug therapy. Mice. Mice, Nude. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Rats. Rats, Sprague-Dawley. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Skin / drug effects. Transplantation, Heterologous. Umbilical Veins / physiology

  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951187.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Protein Kinase Inhibitors; 25X51I8RD4 / Niacinamide; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; F60NE4XB53 / imetelstat
  •  go-up   go-down


27. Teng CC, Chin KJ, Finger PT: Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension. Br J Ophthalmol; 2009 Jun;93(6):837-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cornea / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Ranibizumab

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471005.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down


28. Aldave AJ, Nguyen A: Ocular surface toxicity associated with topical interferon alpha-2b. Br J Ophthalmol; 2007 Aug;91(8):1087-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Conjunctival Neoplasms / drug therapy. Epithelium, Corneal / drug effects. Interferon-alpha / adverse effects
  • [MeSH-minor] Administration, Topical. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome. Visual Acuity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cornea. 2000 Jan;19(1):1-6 [10631999.001]
  • [Cites] Am J Ophthalmol. 2006 Oct;142(4):568-71 [17011846.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):548-52 [11874760.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] Cornea. 2004 Jan;23(1):89-92 [14701965.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • [Cites] Am J Ophthalmol. 1981 Apr;91(4):500-4 [6939330.001]
  • [Cites] Am J Ophthalmol. 1987 Nov 15;104(5):476-80 [3314526.001]
  • [Cites] Cornea. 1989;8(1):58-61 [2924586.001]
  • [Cites] Am J Ophthalmol. 1992 Oct 15;114(4):503-4 [1415465.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Mol Reprod Dev. 1994 Oct;39(2):226-32 [7530016.001]
  • [Cites] Am J Ophthalmol. 1998 Jan;125(1):118-9 [9437331.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):98-103 [10209445.001]
  • [Cites] Ophthalmology. 1999 Sep;106(9):1642-3 [10485523.001]
  • [Cites] J Ocul Pharmacol Ther. 1999 Oct;15(5):401-11 [10530701.001]
  • [Cites] Cornea. 2005 May;24(4):480-1 [15829809.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • (PMID = 17638822.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1954794
  •  go-up   go-down


29. Panda A, Sudan R: Comment on intraoperative use of mitomycin C in excision of ocular surface neoplasia with or without limbal autograft transplantation. Cornea; 2002 Nov;21(8):840-1; author reply 841-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / surgery. Mitomycin / administration & dosage
  • [MeSH-minor] Carcinoma in Situ / drug therapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Corneal Transplantation. Humans. Intraoperative Care. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cornea. 2002 Jan;21(1):12-6 [11805500.001]
  • [ErratumIn] Cornea. 2003 Mar;22(2):189.
  • (PMID = 12410051.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down






Advertisement